Aprea Therapeutics Inchttps://investorshangout.com/Aprea-Therapeutics-Inc-APRE-93373/en-usTue, 20 Oct 2026 02:13:41 GMTCopyright InvestorsHangout.comlouied91: $APRE Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025https://investorshangout.com/post/view?id=6809118https://investorshangout.com/post/view?id=6809118Wed, 31 Dec 2025 17:57:21 GMTlouied91: $APRE Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025https://investorshangout.com/post/view?id=6807667https://investorshangout.com/post/view?id=6807667Thu, 18 Dec 2025 15:32:43 GMTlouied91: Aprea Therapeutics (NASDAQ: $APRE) CEO Oren Gilad Reveals Oncology Breakthroughs on “The Street Rhttps://investorshangout.com/post/view?id=6806192https://investorshangout.com/post/view?id=6806192Wed, 10 Dec 2025 16:57:11 GMTlouied91: $APRE 3Q25 Review & Outlook: Synthetic Lethality Programs Around The WEE1i and ATRi Continue to Phttps://investorshangout.com/post/view?id=6802485https://investorshangout.com/post/view?id=6802485Mon, 17 Nov 2025 20:35:12 GMTlouied91: $APRE Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Updhttps://investorshangout.com/post/view?id=6801523https://investorshangout.com/post/view?id=6801523Wed, 12 Nov 2025 13:49:20 GMTlouied91: $APRE Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals ofhttps://investorshangout.com/post/view?id=6798135https://investorshangout.com/post/view?id=6798135Fri, 24 Oct 2025 13:50:57 GMTlouied91: $APRE Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Cohttps://investorshangout.com/post/view?id=6796321https://investorshangout.com/post/view?id=6796321Wed, 15 Oct 2025 12:59:10 GMT